Short Interest in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Expands By 94.0%

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) was the recipient of a significant increase in short interest in June. As of June 30th, there was short interest totaling 7,748 shares, an increase of 94.0% from the June 15th total of 3,994 shares. Approximately 1.5% of the shares of the stock are short sold. Based on an average daily volume of 35,104 shares, the short-interest ratio is presently 0.2 days.

Eloxx Pharmaceuticals Stock Performance

Shares of NASDAQ:ELOX traded down $0.02 during mid-day trading on Friday, reaching $12.00. The stock had a trading volume of 28,419 shares, compared to its average volume of 21,622. The firm has a market cap of $8.28 million, a P/E ratio of -0.78 and a beta of -1,891.27. Eloxx Pharmaceuticals has a 1 year low of $11.13 and a 1 year high of $17.50. The business has a 50 day moving average of $17.49.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.